Geron

Update in progress

GERN (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Geron Corporation is a commercial-stage biopharmaceutical company focused on oncology therapeutics. Its pipeline includes RYTELO, a telomerase inhibitor for adults with low- to intermediate-1 risk myelodysplastic syndromes and transfusion-dependent anemia; IMerge (Phase 3) for lower-risk MDS; IMpactMF (Phase 3) for relapsed/refractory myelofibrosis; Impress (Phase 2) for higher-risk MDS and AML; IMproveMF (Phase 1) for frontline myelofibrosis; and IMAGINE (Phase 1/2) for relapsed/refractory AML. Founded in 1990, based in Foster City, California.

Company score

Sentiment: -0.10; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.27; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.01; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.09; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqGS (NMS)
LocationUnited States
CEOMr. Harout Semerjian
Founded1990
Employees258
Websitewww.geron.com

Identifiers

ISINUS3741631036
FIGIBBG000GX1891
LEI549300T282D7Z2YESL90
CUSIP374163103
CIK0000886744